Follow the Telix Pharmaceuticals Limited stock price and the full management transaction log of the company, a publicly traded company based in Australia. Shares trade on the AU market, under the authority of ASX. Operating in the Health Care sector, Telix Pharmaceuticals Limited has published 13 public disclosures. Market capitalisation: €5.7bn. The latest transaction was filed on 8 July 2026 (Change in Substantial Holding). Among the most active insiders: There was a change in the interests of the. All data is free.
13
Insider Decl.
n/a
Thresholds
€8
1 ops.
Buy Volume
€26
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Telix Pharmaceuticals Limited Strong Buy (bullish), based on 13 analysts. Average price target: A$23.48.
24Σ signal
Buys €8€26 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,471 of 28,855 companies
35.0
score / 100
Value
33
Quality
38
FCF yld-1.1%
Earn yld-0.1%
EV/EBITDA·
ROE7.4%
Gross mgn53%
Net mgn-0.9%
Debt/EBITDA13.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing targeted therapies for cancer. It specializes in radiopharmaceuticals and precision medicine.